18002-05-6

Basic information

• Product Name: 2-p-tolyl-3H-thieno[3,2-d]pyrimidin-4-one
• Synonyms: 2-p-tolyl-3H-thieno[3,2-d]pyrimidin-4-one
• CAS NO: 18002-05-6
• Molecular Weight: 242.301
• Mol File: 18002-05-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-p-tolyl-3H-thieno[3,2-d]pyrimidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-p-tolyl-3H-thieno[3,2-d]pyrimidin-4-one(18002-05-6)
• EPA Substance Registry System: 2-p-tolyl-3H-thieno[3,2-d]pyrimidin-4-one(18002-05-6)

Safety Data

• Hazardous Substances Data: 18002-05-6(Hazardous Substances Data)

Upstream product

• 478080-01-2 methyl 3-[(4-methylbenzoyl)amino]thiophene-2-carboxylate 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 827-71-4 4-methyl-benzimidic acid ethyl ester 

Downstream Products

• 692737-26-1 C₁₃H₉ClN₂S 

Relevant articles and documents

BICYCLIC DERIVATIVES AS EP4 AGONISTS

The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein ring E represents a partiallysaturated or aromatic 5-membered heterocycle wherein the dotted lines represent an optional double bond and wherein B, C and D each independently represents CH 2, CH, N, NH, S or O and F represents N or C, provided that the 5-membered ring contains 1, 2 or 3 heteroatoms; X represents a direct bond or C 1-4alkanediyl; Y represents N or CH; R1 represents hydrogen or fluoro; R2 represents hydrogen, halo, cyano, C 1-6alkyl, C 1-6alkyloxy, C 1-6alkylcarbonyl or C 1-6alkylcarbonylamino; R3 represents hydrogen, halo, C 1-6alkyl, C 1-6alkyloxy, cyano, nitro, amino or mono-or di(C 1-6alkyl)amino; R4 represents halo; hydroxyl; carboxyl; optionallysubstituted C 1-6alkyl; polyhaloC 1-6alkyl; C 1-6alkyloxycarbonyl; polyhaloC 1-6alkyloxy; optionallysubstituted C 2-6alkenyl; cyano; nitro; NR10 R11; C 1-6alkylthio; optionally substituted C 1-6alkyloxy; or two adjacent R4 substituents may be taken together; n represents an integer of value 1, 2 or 3; m represents aninteger of value 1, 2 or 3; provided that R3 may onlybe other than hydrogen if at least one of R1 or R2 is other than hydrogen; and provided that2,6- bis(1,1-dimethylethyl)-4-[6-(2-phenylethoxy)-1H-purin-2-yl]-phenol is not included; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a disease by activating the EP4 receptor.